Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Tapped Density: Comprehensive Analysis For Pharmaceutical Formulation Optimization

NOV 17, 202669 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium Tapped Density represents a critical physical parameter in pharmaceutical formulation development, directly influencing powder flow characteristics, compaction behavior, and tablet manufacturing efficiency. As an internally cross-linked derivative of sodium carboxymethylcellulose, croscarmellose sodium exhibits unique density properties that distinguish it from conventional disintegrants, with tapped density values typically ranging from 0.50 to 0.75 g/cm³ depending on particle size distribution and manufacturing conditions 5,6,7. Understanding the relationship between tapped density and formulation performance enables formulators to optimize direct compression processes, predict blend uniformity, and achieve consistent tablet quality in high-speed production environments.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Density-Influencing Characteristics Of Croscarmellose Sodium

Croscarmellose sodium is an internally cross-linked polymer of carboxymethylcellulose sodium, produced through controlled pH reduction and thermal treatment during manufacturing 2,4. The cross-linking process creates a three-dimensional fibrous network structure that fundamentally determines its density characteristics 5,6,7. Unlike non-cross-linked sodium carboxymethylcellulose, which forms pasty gums upon moisture exposure, the cross-linked architecture maintains particle integrity even when hydrated, preserving the original density profile 11.

The fibrous morphology of croscarmellose sodium directly impacts its tapped density measurements. Standard commercial grades exhibit particle size distributions where 90% of particles are ≤44.5 μm 11, though specialized fine particle grades demonstrate median particle sizes (D50) ranging from 5 μm to 36 μm with volume mean diameters (D[4,3]) of 40 μm or less 5,6,7. These fine particle variants typically possess specific surface areas of 0.3 m²/g or greater 5,6,7, which correlates with modified packing behavior during tapped density determination. The degree of substitution in pharmaceutical-grade croscarmellose sodium ranges from 0.60 to 0.85 2, influencing both the hydrophilicity and the inter-particle interactions that govern bulk and tapped density relationships.

The cross-linking density itself modulates the rigidity of individual particles. Higher cross-linking degrees produce more rigid fibrous structures that resist deformation under tapping stress, potentially yielding higher tapped density values compared to lightly cross-linked variants. Manufacturing processes employing sulfuric acid catalysis in aqueous organic solvents 2 or hydrochloric acid in ethanol-water systems 4 can be tuned to control cross-linking extent, thereby indirectly controlling the final tapped density profile of the excipient.

Tapped Density Measurement Protocols And Standardization For Croscarmellose Sodium

Tapped density determination for croscarmellose sodium follows standardized pharmacopeial methods, typically employing a graduated cylinder and mechanical tapping apparatus. The procedure involves measuring the volume occupied by a known mass of powder after a defined number of taps (usually 500 to 1250 taps at a frequency of approximately 250 taps per minute). For croscarmellose sodium, initial bulk density values are recorded, followed by tapped density after the powder bed reaches a constant volume 3.

In formulation studies involving croscarmellose sodium, tapped density is evaluated alongside bulk density to calculate derived parameters such as Hausner's Ratio and Compressibility Index (Carr's Index) 3. Hausner's Ratio, defined as the ratio of tapped density to bulk density, provides insight into powder flowability; values below 1.25 indicate good flow, while values above 1.5 suggest poor flow characteristics. Compressibility Index, calculated as [(Tapped Density - Bulk Density) / Tapped Density] × 100, similarly correlates with flow properties, with values below 15% indicating excellent flow and values above 25% indicating poor flow 3.

For croscarmellose sodium, typical tapped density values range from 0.50 to 0.75 g/cm³, though this can vary based on particle size distribution and moisture content. Fine particle croscarmellose sodium grades with D50 values of 5-25 μm 5,6,7 may exhibit slightly lower tapped densities due to increased inter-particle friction and surface area effects. Conversely, standard grades with larger particle size distributions may demonstrate higher tapped densities as particles pack more efficiently under mechanical tapping.

Environmental conditions during measurement significantly affect results. Croscarmellose sodium is hygroscopic, and moisture uptake can alter both bulk and tapped density values. Standardized testing protocols therefore specify controlled humidity conditions (typically 40-60% relative humidity at 20-25°C) to ensure reproducibility. Additionally, the fibrous nature of croscarmellose sodium means that electrostatic effects can influence packing behavior; grounding the measurement apparatus and using anti-static treatments may be necessary for consistent results.

Relationship Between Croscarmellose Sodium Tapped Density And Formulation Performance

The tapped density of croscarmellose sodium directly influences several critical formulation parameters in pharmaceutical tablet manufacturing. First, it affects the volumetric dosing accuracy in direct compression processes. Powders with consistent tapped density values exhibit more predictable fill volumes in tablet dies, reducing weight variation in the final dosage form 3. When croscarmellose sodium is used at concentrations of 10-15% w/w 12,16—significantly higher than the conventional 2-5% w/w range 9,12—its contribution to the overall blend density becomes substantial, necessitating careful characterization of its tapped density profile.

Second, tapped density correlates with the compaction behavior of powder blends. Croscarmellose sodium with higher tapped density values typically requires greater compression forces to achieve target tablet hardness, as the particles are already in a more densely packed state. This relationship is particularly important when formulating tablets by direct compression, where the blend must flow uniformly into the die cavity and then compact efficiently under applied pressure. Studies on ibandronate sodium formulations demonstrated that combining microcrystalline cellulose (median particle size D50 = 100 μm) with 10-15% w/w croscarmellose sodium achieved optimal dissolution profiles 12,16, suggesting that the tapped density of this specific croscarmellose sodium concentration range supports both adequate flow and effective disintegration.

Third, the tapped density of croscarmellose sodium influences segregation potential in powder blends. When the tapped density of croscarmellose sodium differs significantly from that of other excipients (such as microcrystalline cellulose, mannitol, or active pharmaceutical ingredients), segregation during handling and feeding can occur, leading to content uniformity issues. Formulators must therefore match the density profiles of blend components or employ granulation techniques to mitigate segregation risks 3.

Fourth, tapped density impacts the disintegration efficiency of tablets. Croscarmellose sodium functions as a superdisintegrant through wicking, swelling, and deformation recovery mechanisms 5,6,7. Tablets compressed from blends with higher tapped density values may exhibit slower disintegration times if the croscarmellose sodium particles are too tightly packed to swell effectively upon contact with dissolution media. Conversely, blends with lower tapped density may disintegrate rapidly but suffer from poor mechanical strength. Optimizing the tapped density of croscarmellose sodium-containing blends thus requires balancing disintegration speed with tablet robustness.

Particle Size Distribution Effects On Croscarmellose Sodium Tapped Density

Particle size distribution exerts a profound influence on the tapped density of croscarmellose sodium. Fine particle grades with median particle sizes (D50) of 5-36 μm and volume mean diameters (D[4,3]) ≤40 μm 5,6,7 exhibit distinct tapped density profiles compared to standard grades with 90% of particles ≤44.5 μm 11. The fine particle variants typically demonstrate 10th percentile particle sizes (D10) ≤15 μm and 90th percentile particle sizes (D90) ≤80 μm 5,6,7, resulting in a broader particle size distribution that can either increase or decrease tapped density depending on the packing efficiency of the multimodal distribution.

Smaller particles generally possess higher specific surface areas (≥0.3 m²/g for fine particle croscarmellose sodium 5,6,7), which increases inter-particle friction and can reduce tapped density by hindering efficient packing. However, if the particle size distribution includes a sufficient fraction of fines that can fill interstitial voids between larger particles, tapped density may actually increase. This phenomenon is observed in polydisperse systems where bimodal or trimodal distributions optimize packing efficiency.

Manufacturing processes that control particle size also indirectly control tapped density. For example, the solvent-based cross-linking method using sulfuric acid in aqueous organic solvents 2 can be adjusted to produce croscarmellose sodium with specific particle size distributions by varying reaction temperature (40-75°C), reaction time (0.5-4.0 hours), and solvent composition. Post-synthesis processing steps such as drying (70-90°C), crushing, and sieving through 200 mesh screens 2 further refine the particle size distribution and, consequently, the tapped density.

In formulation development, selecting the appropriate particle size grade of croscarmellose sodium is essential for achieving target tapped density values. For instance, in fast-dissolving tablet formulations of etodolac, the evaluation of mass-volume relationships including tapped density was critical for ensuring adequate flow properties and compressibility 3. Similarly, in amonavir tablet formulations, the detection method for croscarmellose sodium content 1 implicitly relies on consistent particle characteristics, including tapped density, to ensure accurate quantification via HPLC-CAD.

Comparative Analysis: Croscarmellose Sodium Tapped Density Versus Other Superdisintegrants

Croscarmellose sodium's tapped density profile can be contextualized by comparing it with other superdisintegrants commonly used in pharmaceutical formulations. Sodium starch glycolate (e.g., Explotab®, Primogel®), a cross-linked carboxymethyl potato starch, typically exhibits tapped density values in the range of 0.60-0.80 g/cm³, slightly higher than many croscarmellose sodium grades 5,6. This difference arises from the more compact granular morphology of sodium starch glycolate compared to the fibrous structure of croscarmellose sodium 5,6,7.

Crospovidone (cross-linked polyvinylpyrrolidone, e.g., Polyplasdone XL®, Kollidon CL®) is water-insoluble and hydrophilic, functioning primarily through swelling 5,6,7. Crospovidone generally has a lower tapped density (approximately 0.30-0.50 g/cm³) due to its highly porous, sponge-like particle structure. This lower tapped density can be advantageous for formulations requiring rapid disintegration but may pose challenges for direct compression due to poor flow and compaction properties.

The fibrous nature of croscarmellose sodium 5,6,7 confers a unique advantage: it maintains particle integrity upon hydration, avoiding the gelling behavior seen with non-cross-linked sodium carboxymethylcellulose 11. This structural stability ensures that tapped density measurements remain consistent across batches and storage conditions, provided moisture content is controlled. In contrast, sodium starch glycolate can gel at high concentrations, potentially altering its effective density in the presence of moisture 5,6.

From a formulation perspective, the intermediate tapped density of croscarmellose sodium (0.50-0.75 g/cm³) positions it as a versatile excipient. It provides better flow characteristics than crospovidone while offering superior disintegration efficiency compared to sodium starch glycolate at equivalent concentrations. This balance is particularly valuable in direct compression formulations where both flow and disintegration are critical quality attributes 3,12,16.

Influence Of Croscarmellose Sodium Concentration On Blend Tapped Density

The concentration of croscarmellose sodium in a powder blend significantly affects the overall tapped density of the mixture. At conventional disintegrant levels (2-5% w/w), the impact on blend tapped density is relatively modest, as the bulk of the blend density is determined by the primary excipients such as microcrystalline cellulose, lactose, or mannitol 9,12. However, at elevated concentrations (10-15% w/w), as employed in certain ibandronate sodium formulations 12,16, croscarmellose sodium becomes a major contributor to the blend's density profile.

Microcrystalline cellulose, a common diluent in direct compression, typically has a tapped density of 0.40-0.50 g/cm³ (for grades like Avicel PH-101 15). When combined with croscarmellose sodium at 10-15% w/w, the resulting blend tapped density will be a weighted average of the component densities, adjusted for packing interactions. If croscarmellose sodium has a tapped density of 0.60 g/cm³ and microcrystalline cellulose 0.45 g/cm³, a blend containing 12% croscarmellose sodium and 80% microcrystalline cellulose would have an estimated tapped density of approximately 0.47 g/cm³, assuming ideal mixing and no synergistic packing effects.

However, real-world blends often exhibit non-ideal behavior. The fibrous morphology of croscarmellose sodium can create a scaffolding effect within the blend, increasing void spaces and reducing tapped density below the theoretical weighted average. Conversely, fine particles of croscarmellose sodium may fill interstitial voids between larger microcrystalline cellulose particles, increasing tapped density. Empirical measurement is therefore essential for accurate characterization 3.

High concentrations of croscarmellose sodium also influence the Hausner's Ratio and Compressibility Index of the blend. Blends with 10-15% croscarmellose sodium may exhibit Hausner's Ratios approaching 1.3-1.4, indicating fair to passable flow 3. This necessitates careful optimization of other excipients (e.g., glidants like colloidal silicon dioxide or lubricants like magnesium stearate) to ensure adequate flow for high-speed tablet production.

In taste-masking applications, croscarmellose sodium is used at 1-10% w/w in the final tablet formulation 10, where it serves dual roles as a coating agent and disintegrant. At these concentrations, the tapped density of the coated particles (active ingredient coated with croscarmellose sodium) will differ from that of uncoated particles, affecting the overall blend density and requiring re-evaluation of flow and compaction parameters 10.

Experimental Determination And Quality Control Of Croscarmellose Sodium Tapped Density

Quality control protocols for croscarmellose sodium must include rigorous tapped density testing to ensure batch-to-batch consistency. Pharmacopeial monographs (e.g., USP, EP, JP) specify acceptable ranges for tapped density, though these ranges can vary depending on the grade and intended application. Manufacturers typically establish internal specifications based on historical data and formulation requirements.

The experimental procedure for tapped density determination involves the following steps:

  1. Sample Preparation: Accurately weigh a representative sample of croscarmellose sodium (typically 50-100 g) and transfer it to a graduated cylinder (usually 100 mL or 250 mL capacity). Ensure the sample is free from agglomerates by gently breaking up any lumps without applying excessive force that could alter particle size distribution.

  2. Initial Volume Measurement: Record the initial unsettled bulk volume (V₀) to calculate bulk density (ρ_bulk = mass / V₀).

  3. Mechanical Tapping: Subject the cylinder to a defined number of taps (e.g., 500, 1250, or until volume change between successive measurements is <2%) using a standardized tapping apparatus (e.g., Stampfvolumeter, Erweka, or equivalent). The tapping frequency is typically 250 taps per minute with a drop height of 3 mm ± 0.2 mm.

  4. Final Volume Measurement: Record the final tapped volume (V_t) and calculate tapped density (ρ_tapped = mass / V_t).

  5. Derived Parameters: Calculate Hausner's Ratio (HR = ρ_tapped / ρ_bulk) and Compressibility Index (CI = [(ρ_tapped - ρ_bulk) / ρ_tapped] × 100) 3.

For croscarmellose sodium, typical acceptance criteria might specify tapped density within ±10% of a target value (e.g., 0.60 ± 0.06 g/cm³), Hausner's Ratio <1.4, and Compressibility Index <25%. Deviations outside

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATION INC.Pharmaceutical tablet formulations requiring rapid disintegration, particularly direct compression processes where controlled tapped density (0.50-0.75 g/cm³) ensures optimal powder flow, blend uniformity, and compaction behavior.Ac-Di-Sol (Fine Particle Croscarmellose)Fine particle croscarmellose with median particle size (D50) of 5-36 μm and volume mean diameter ≤40 μm, specific surface area ≥0.3 m²/g, providing enhanced disintegration through wicking, swelling, and deformation recovery due to fibrous structure while maintaining particle integrity upon hydration.
ANHUI SHANHE PHARMACEUTICAL EXCIPIENTS CO. LTD.Pharmaceutical excipient manufacturing for tablet disintegrants where consistent tapped density and particle size distribution are critical for batch-to-batch quality control and formulation performance.Croscarmellose Sodium (Pharmaceutical Excipient)Solvent-based cross-linking method using sulfuric acid in aqueous organic solvents at controlled temperature (40-75°C) and reaction time (0.5-4.0h), producing croscarmellose sodium with degree of substitution 0.60-0.85, enabling precise control of cross-linking degree and tapped density profile.
LABORATORIOS LICONSA S.A.Direct compression tablet manufacturing for bisphosphonate drugs requiring fast dissolution profiles, where elevated croscarmellose sodium concentration (10-15% vs conventional 2-5%) balances flow properties, compressibility, and disintegration efficiency.Ibandronate Sodium Tablet FormulationCombination of microcrystalline cellulose (median particle size D50=100 μm) with 10-15% w/w croscarmellose sodium achieving >60% dissolution within 5 minutes and >85% within 15 minutes, optimizing tapped density for direct compression while ensuring rapid drug release.
FMC CORPORATIONTaste-masked pharmaceutical tablets for bitter-tasting active ingredients where croscarmellose sodium coating maintains particle integrity and predictable density profiles during handling, blending, and compression operations.Croscarmellose Sodium Taste-Masking SystemFluidized bed coating process using croscarmellose sodium at 1-10% w/w in final tablet formulation, providing dual functionality as taste-masking coating agent and tablet disintegrant while preserving rapid disintegration characteristics and maintaining consistent tapped density in coated particle blends.
JISIKAI (SUZHOU) PHARMACEUTICAL CO. LTD.Pharmaceutical quality control laboratories requiring precise measurement of croscarmellose sodium content to verify formulation consistency, where tapped density and related flow properties directly impact tablet manufacturing efficiency and product quality.Amonavir Tablet Quality Control SystemHPLC-CAD detection method for accurate quantification of croscarmellose sodium content in tablet formulations, ensuring consistent tapped density specifications and excipient quality control without interference from other tablet components.
Reference
  • Method for detecting content of croscarmellose sodium in amonevir tablet
    PatentInactiveCN118032979A
    View detail
  • Method for preparing pharmaceutical adjuvant-croscarmellose sodium from sodium carboxymethylcellulose by solvent method
    PatentInactiveCN101914212A
    View detail
  • A process for formulating fast dissolving tablets of etodolac and its composition thereof
    PatentActiveZA202302375B
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png